Mutations of Ros Differentially Effecting Signal Transduction Pathways Leading to Cell Growth Versus Transformation*

(Received for publication, July 31, 1996, and in revised form, October 15, 1996)

Cong S. Zong , Joseph L.-K. Chan , Sheng-Kai Yang and Lu-Hai Wang Dagger

From the Department of Microbiology, Mount Sinai School of Medicine, New York, New York 10029

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
REFERENCES


ABSTRACT

The signaling functions of the oncogenic protein-tyrosine kinase v-Ros were studied by systematically mutating the tyrosine residues in its cytoplasmic domain. The carboxyl mutation of Tyr-564 produces the most pronounced inhibitory effect on v-Ros autophosphorylation and interaction with phospholipase Cgamma . A cluster of 3 tyrosine residues, Tyr-414, Tyr-418, and Tyr-419, within the PTK domain of v-Ros plays an important role in modulating its kinase activity. The mutant F419 and the mutant DI, deleting 6-amino acids near the catalytic loop, retain wild type protein tyrosine kinase and mitogenic activities, but have dramatically reduced oncogenicity. Both mutant proteins are able to phosphorylate or activate components in the Ras/microtubule-associated protein kinase signaling pathway. However, F419 mutant protein is unable to phosphorylate insulin receptor substrate 1 (IRS-1) or promote association of IRS-1 with phosphatidylinositol 3-kinase. This tyrosine residue in the context of the NDYY motif may define a novel recognition site for IRS-1. Both F419 and DI mutants display impaired ability to induce tyrosine phosphorylation of a series of cytoskeletal and cell-cell interacting proteins. Thus the F419 and DI mutations define v-Ros sequences important for cytoskeleton signaling, the impairment of which correlates with the reduced cell transforming ability.


INTRODUCTION

Autophosphorylation of receptor protein-tyrosine kinase (RPTKs)1 is one of the earliest detectable events in response to binding of their cognate ligand. This step has two pivotal roles, one is to activate the intrinsic PTK activity of the receptor and the other is to create site(s) for substrate protein interaction, both of which are essential in initiating pathways of signal transduction mediated by the receptor PTKs (1).

The oncogene v-ros encoded by the avian sarcoma virus UR2 is a truncated receptor-like PTK (2). The proto-oncogene c-ros codes for a receptor PTK with an extended extracellular domain (3-5). v-ros differs from c-ros in that all but 21 nucleotides that code for the extracellular domain of c-ros are truncated and the remaining gene is fused in frame at its 5' end to viral gag sequences. As a result, v-ros codes for a gag-Ros transmembrane fusion protein of 68 kilodaltons called P68gag-ros that is constitutively active (6). In addition, there are minor alterations in the transmembrane (TM) domain and carboxyl region of v-Ros in comparison with c-Ros (7). The kinase domain of Ros is highly homologous with the kinase domains of insulin receptor (IR) and insulin like growth factor I receptor (IGFR) (4). The PTK domain of Ros has two distinct sequence features in comparison with members of the Src family and other receptor PTKs (4). One is a cluster of 3 tyrosine residues consisting of a single tyrosine followed by twin tyrosines 4 residues downstream. The other is a 6-amino acid insertion 3 amino acids downstream of the predicted PTK catalytic loop defined from the crystal structure of the kinase domain of IR (8). These characteristic sequence features of the v-Ros PTK domain are also shared by its closely related RPTKs, IR, and IGFR (4). Mutation of the twin tyrosines or all 3 tyrosines in IR or IGFR resulted in dramatic reduction in their PTK activity (9-12). The importance of these tyrosine residues was further suggested by the crystal structure of the PTK domain of IR (8). In this study, it was suggested that the middle tyrosine residue (Tyr-1162) of IR affects gating of the catalytic site by controlling the accessibility of ATP and substrate binding. Based on the amino acid sequence homology to IR, it is likely that the triple tyrosine residues of Ros also play an important role in regulating its catalytic activity.

The interaction between an activated receptor PTK and some of its substrates is mediated by a family of src-homology domain 2 or 3 (SH2/SH3)-containing proteins (13). Although RPTKs in general do not contain SH2 or SH3 motifs, most of their downstream signaling proteins thus far identified contain the SH2 and/or SH3 domains (1, 13, 14). Their association with RPTKs is facilitated by the tyrosine phosphorylation of specific sites on the receptors in response to the binding of ligands to receptors' extracellular domains. For example, phosphorylation of specific tyrosine residues on platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) receptors is required for binding of several of their downstream signaling molecules including GAP, PI3 kinase, and PLCgamma (reviewed in Cantley (1)). In contrast, IR and IGFR bind IRS-1 and Shc at an NPXY motif in the receptors' juxtamembrane domains (15-17).

The Shc- and Grb2-mediated activation of Ras/MAP kinase pathway is involved in the mitogenic signaling by growth factors and cytokines (1, 18). Other signaling pathways involving PLCgamma , IRS-1, and PI3 kinase have also begun to be elucidated. IRS-1 serves as the major adaptor for recruiting other signaling molecules upon stimulation of IR by insulin and most likely of IGFR by IGF-1 (19). Tyrosine-phosphorylated IRS-1 is capable of binding to and activating PI3 kinase (20). Mutation of the IRS-1 recognition motif NPEY diminishes insulin-induced tyrosine phosphorylation of IRS-1 and activation of PI3 kinase (17).

Reorganization of cytoskeletal structure and alteration of membrane properties represents an important component of the process of malignant cell transformation. However, the processes involved in cytoskeletal signaling remained unclear. Ever increasing attention has been directed toward understanding the transmission of signals from the interaction of integrins and their extracellular matrix ligands, particularly at adhesion plaques (21). The focal adhesion protein-tyrosine kinase, pp125 FAK, colocalizes with the integrin receptor in cellular focal adhesions and is activated upon engagement of the integrin receptor with its ligand or upon Src transformation (22, 23). Cadherin and its associated catenins constitute other important molecules in cytoskeleton-mediated signaling. Cadherins mediate Ca2+-dependent cell-cell adhesion via homophilic interaction of these cell surface molecules (24).

If specific tyrosine residues of an oncogenic RPTK interact with different intermediate substrates leading to distinctive signal transduction pathways, it may, therefore, be possible to impair specific pathways responsible for different biological effects by mutating those substrates interacting tyrosine residues. To explore the functional role of specific tyrosine residues of the oncogenic v-Ros, particularly with respect to their roles in mitogenic versus transforming activity, we have systematically mutated all of the tyrosine residues in the cytoplasmic domain of v-Ros. In addition, we have also removed the 6-amino acid insertion in the v-Ros catalytic domain. These mutants allowed us to identify the tyrosine residues of v-Ros important for regulating PTK activity and interaction with specific substrates. They also allow the differentiation of signaling pathways leading to mitogenicity versus morphological transformation and anchorage-independent growth.


EXPERIMENTAL PROCEDURES

Cells and Viruses

Chicken embryo fibroblasts (CEF) were prepared from 11-day-old embryos and maintained according to the previously published procedure (6, 7, 25). The CEF were maintained as monolayer culture except in the colony formation assay, where they were suspended in the agar medium. Unless otherwise specified, CEF were maintained in F10 medium containing 5% calf serum and 1% chick serum (6, 7, 25). Molecularly cloned avian sarcoma virus UR2 and its helper virus UR2AV have been described (2, 7).

Biological Assay

Cell transformation was monitored by morphological change and anchorage-independent growth as described previously (7, 11, 25, 26). For colony formation in methyl cellulose, medium containing 1.3% pure methyl cellulose was used for the top layer on the same platform of bottom layer agar.

Antibodies

Anti-Ros and anti-IRS-1 antibodies were made in our laboratory and have been described (6, 11). Anti-MAP kinase polyclonal antibody TR10 was a gift from M. Weber, Anti-annexin II polyclonal antibody was a gift from T. Hunter. Monoclonal antibodies for cortactin, tensin, and CAS were gifts from T. Parsons and A. Bouton. Anti-p190 Rho/GAP polyclonal antibody was a gift from S. Parsons. Anti-Grb2 polyclonal antibody was a gift from B. Mayer. Antibodies for FAK, beta - and gamma -catenin and an alkaline phosphatase-coupled anti-phosphotyrosine (Tyr(P)) antibody RC20 were purchased from Transduction Lab. Antibodies for PLCgamma and PI3 kinase were purchased from Upstate Biotechology Inc. Anti-beta 1-integrin and anti-N-cadherin were purchased from Sigma and Zymed Laboratories Inc., respectively.

Construction of pBUR2

The plasmid pUR2H1 contains the full-length UR2 genome cloned at the HindIII site of pBR322 (2, 7). The UR2 genome in this plasmid is permuted with respect to the HindIII site at the 3' region of the UR2 genome. To facilitate DNA transfection and expression of viral genes, a nonpermuted UR2 plasmid was reconstructed. This was done by isolating the 2.3-kilobase pair PstI to NruI fragment containing the entire gag-Ros coding sequence from pUR2H1 and using it to replace the gag-IGFR sequence in a nonpermuted viral plasmid pBUIGFR-II constructed previously (26). The resulting plasmid was named pBUR2 which served as the parental plasmid for mutant construction.

Construction of Mutants

The mutants were engineered by a M13-mediated mutagenesis kit (Promega) described previously (11) or polymerase chain reaction using oligonucleleotides containing specific base changes. The sites of mutagenesis was sequenced to confirm the mutation.

Protein Analysis

Cellular protein extraction, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, and Western blotting have been described elsewhere (6, 26). In vitro assays of PTK, PI3 kinase, and MAP kinase followed those described previously (7, 25).


RESULTS

Construction of v-Ros Site-specific Mutants

All the tyrosine residues in the cytoplasmic domain of P68gag-ros were converted individually, or in combination to phenylalanines (Fig. 1). The viruses encoding the mutant v-Ros proteins were named according to the positions of the mutated tyrosine residues (2) with the exception of double and triple mutants F2, F3, and F4. In addition, a unique 6-amino acid insertion located 3 amino acids downstream of the predicted catalytic loop was deleted to generate the mutant DI.


Fig. 1. Mutants of the UR2 v-Ros. The UR2 encoded P68gag-ros is shown with different structural domains indicated. The numbers correspond to the amino acid positions (2). TM1 deletes a 3-amino acid insertion in the TM domain of UR2 P68 and has been described (25). The kinase activity and relative mitogenic and cell transforming activities of each mutant are indicated. The ± means a decrease of activity to different extents as detailed in the text. The kinase activity of DI protein is inactive in vitro, but is active in vivo.
[View Larger Version of this Image (17K GIF file)]


Biological Properties of the v-Ros Mutants

Two or three independent clones of each mutant v-Ros expression plasmid were co-transfected with UR2AV helper virus DNA into CEF to assess their biological activity. Most mutants showed both mitogenic and transforming activity indistinguishable from that of parental UR2 (Fig. 1). However, the mutant F2 containing the Y418F and Y419F double mutation had only a residual transforming activity. The triple mutant F3 had undetectable mitogenic and transforming activity. Mutants F419 and DI showed dramatically reduced transforming ability as reflected in morphological alteration of the transfected cells (data not shown) and ability of the cells to form colonies in soft agar (Fig. 2). However, both mutants displayed wild-type mitogenic activity when infected cells were maintained as monolayer culture in either 5 or 0.5% serum-containing medium (Fig. 2).


Fig. 2. Biological activities of F419 and DI mutants. A, colony formation of UR2- and mutant-infected cells. CEF and mutant-infected cells were seeded in soft agar at 105 cells/60-mm dish. The photographs were taken 2 weeks later. B and C, growth rate of normal and various viruses-infected cells. 1.2 × 105 cells were seeded per 6-cm dish and incubated with regular medium containing 5% serum on day 0. On day 1, the adhered viable cells were counted, and the cultures were switched to either 5% (B) or 0.5% (C) serum-containing medium. Cell numbers from duplicate dishes were counted every other day thereafter, and the cultures were replenished with fresh medium on the day of counting.
[View Larger Version of this Image (50K GIF file)]


The double mutant F4 displayed a further reduced transforming capability in comparison with F419 (data not shown) despite the fact that a single mutation of Tyr-564 produced no detectable difference from UR2. This result indicates that the effect of the Tyr-564 mutation, which impairs the interaction of v-Ros with PLCgamma (see below), can only be detected in the background of a weak transforming protein such as F419.

Tumorigenicity of F419, DI, and the parental UR2 was compared. The result (Table I) shows that both mutants have dramatically reduced tumorigenicity. In fact, none of the chicks succumbed to the tumors induced by the mutants during the 1-month observation period (Table I) and even in an extended period of 2 months in a separate experiment (data not shown). This result is consistent with the impaired ability of the two mutants in promoting anchorage independent growth, but does not correspond to their mitogenic activity in monolayer cultures.

Table I.

Tumorigenicity

Cell-free overnight medium from fully infected cultures producing similar amount of Ros proteins were used for injecting 1-day-old chicks. Each chick was injected with 0.1 ml of virus stock containing about 105 infectious units per wing web. Control chicks were similarly injected with regular medium.
Treatment Tumor incidence Onseta Average sizeb Death incidencec

days mm2
Control 0 /4
UR2 6 /6 7 -10 239.2 6 /6
F419 6 /6 17 -21 66.5 0 /6
DI 4 /6 21 -30 37.7 0 /6

a  Days after injection when tumors were first visible.
b  The size of tumors were measured by their surface area 1 week after their detection. The average size was obtained by dividing the sum of total tumor area by the number of tumors measured.
c  The number of chicks succumbed to tumors 1 month after virus injection when the experiment was terminated. All the chicks inoculated with UR2 died within 4 weeks after injection.

PTK Activity of the Mutant v-Ros Proteins

The kinase activities of mutant v-Ros proteins were analyzed by in vitro auto- and trans-phosphorylation, in vivo tyrosine phosphorylation of the Ros proteins, as well as their ability to phosphorylate cellular proteins (Fig. 3). Mutation of both Tyr-418 and Tyr-419 (F2) resulted in a greatly reduced kinase activity, particularly its in vivo autophosphorylation and ability to phosphorylate cellular substrates. Only a residual in vitro kinase activity and no detectable in vivo kinase activity was detected for the F3 protein containing the triple mutation of Y414F, Y418F, and Y419F. These results suggest that these residues, particularly Tyr-418 and Tyr-419, play a major role in modulating the PTK activity of v-Ros. Surprisingly, despite a lack of detectable activity in the in vitro autophosphorylation (Fig. 3A) and phosphorylation of the exogenously added substrate, enolase (Fig. 3B), the DI protein, appears to have wild-type kinase activity intracellularly as reflected in its in vivo autophosphorylation (Fig. 3A) and phosphorylation of cellular proteins (Fig. 3C). The apparent paradox of the in vitro and in vivo kinase activity of the DI protein will be discussed. As expected, the DI protein exhibited a slightly faster mobility in the SDS-gel when detected with anti-Ros antibody (Fig. 3, A and B, bottom panels). The F564 protein containing the carboxyl-terminal tyrosine to phenylalanine mutation appears to be underphosphorylated and to have a faster mobility when detected in Western blotting with anti-Tyr(P) antibody (Fig. 3 A and C). However, F564 protein has no detectable decrease in in vitro kinase activity, although its phosphorylated products also appear to be down-shifted in gel mobility in comparison with those of the parental v-Ros (Fig. 3A, top panel and other data not shown). The mobility downshifting of in vivo phosphorylated protein was also apparent for the F4 protein containing the Y419F and Y564F double mutation (Fig. 3A). Again, no detectable difference of in vitro or in vivo kinase activity was observed for the F4 protein. The expression levels of the various mutant v-Ros proteins in transfected cells was comparable, with the exception of F2 and F3, where the expression levels were 4-5-fold lower. More protein lysates from F2- and F3-infected cells were needed in order to normalize the Ros protein in the experiments shown in Fig. 3. Except for the mutants described above, no effect on the in vitro or in vivo PTK activity was observed for the rest of mutants.


Fig. 3. PTK activities of mutant v-Ros proteins. A, in vitro kinase activity and in vivo autophosphorylation. Equal amounts of cell lysates from control and mutant-infected mass CEF cultures were immunoprecipitated with anti-Ros and subjected to in vitro kinase assay (upper panel), Western blotting with anti-Tyr(P) antibody (middle panel), or anti-Ros antibody (bottom panel). Four- to 5-fold more lysates were used for F2 and F3 in order to normalize the amount of Ros protein. B, in vitro kinase activity toward the exogenous substrate enolase. The condition was the same as in A, except that 4 µg of acid-treated enolase (6) were added to the assay. Upper panel, kinase activity; lower panel, Ros protein amount. C, tyrosine phosphorylation of cellular proteins. Control and mutant-infected CEF were treated with 200 µM Na3VO4 for 4 h. Total cell proteins were extracted with SDS-containing buffer (10 mM Tris, pH 7.4, 5 mM EDTA, 1% SDS, 1 mM Na3VO4, 1 mM Na3Mo4 1 mM phenylmethylsulfonyl fluoride, and 1% Trasylol). Twenty µg each of total cell lysates were separated by SDS-polyacrylamide gel electrophoresis, followed by Western blotting with anti-Tyr(P) antibody (RC20). The arrow indicates the Ros protein bands.
[View Larger Version of this Image (36K GIF file)]



Fig. 4. Tyrosine phosphorylation of PLCgamma , 5C2, and Shc. Cells were treated with 200 µM Na3VO4 for 4 h prior to protein extraction with radioimmune precipitation buffer (50 mM Tris, pH 7.4, 5 mM EDTA, 150 mM NaCl, 1 mM Na3VO4, 1% deoxycholic acid, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, and 1% Trasylol). 500 µg each of cell lysates was immunoprecipitated with anti-PLCgamma (A), 5C2 (B), or anti-Shc (C) antibody, and subjected to Western blotting with anti-Tyr(P) antibody (RC20).
[View Larger Version of this Image (33K GIF file)]


Phosphorylation and Activation of Specific Signaling Proteins

To identify the tyrosine site(s) required for interaction of v-Ros with specific substrates, the mutant proteins were compared for their ability to phosphorylate or activate various signaling molecules. Our results (Fig. 4) show that with the exception of the kinase-defective mutants, F2 and F3, all the mutants were capable of inducing tyrosine phosphorylation of Shc and 5C2, an 88-kDa cellular protein we previously identified to be a prominent substrate of v-Ros (25). In addition to F2 and F3, the F564 protein was also unable to cause tyrosine phosphorylation of PLCgamma despite its wild-type kinase activity level. As expected this is also true for F4. Therefore, Tyr-564 may serve as PLCgamma recognition site directly or be critical for the formation of a PLCgamma site elsewhere in the protein. Our observation that F564 has a wild-type transforming activity level indicates that phosphorylation of PLCgamma is not essential for this activity. However, since mutation of Tyr-564 in the background of F419 further reduces its transforming ability, it is likely that phosphorylation of PLCgamma may enhance cellular transformation by v-Ros.

Activation of MAP Kinase

To further explore the biochemical basis for the reduced transforming activity of F419 and DI, we examined the ability of these mutants to activate MAP kinase, a downstream effector of the Ras signaling pathway. Consistent with their ability to induce tyrosine phosphorylation of Shc, both the F419 and DI proteins are able to promote association of Grb2 with three distinct tyrosine phosphorylated proteins with gel mobilities corresponding to those of Shc proteins (46, 52, and 66 kDa). The mutants also activate MAP kinase as efficiently as the wild type v-Ros (Fig. 5). This is consistent with the observed mitogenic activity of F419 and DI mutants.


Fig. 5. Association of Shc with Grb2 and activation of MAP kinase. A, Grb2-associated Shc. Cells were treated with 200 µM Na3VO4 for 4 h prior to protein extraction with Nonidet P-40 buffer (20 mM Tris pH 7.4, 5 mM EDTA, 150 mM NaCl, 1 mM Na3VO4, 1% Nonidet P-40, 1 mM phenylmethylsulfonyl fluoride, and 1% Trasylol). 500 µg each of cell lysates were immunoprecipitated with anti-Grb2, followed by Western blotting with anti-Tyr(P) antibody (RC20) (upper panel) or anti-Grb2 (lower panel). B, activation of MAP kinase. 400 µg each of radioimmune precipitation buffer cell lysates were immunoprecipitated with anti-MAP kinase TR10, and half of the immunoprecipitates was used for MAP kinase assay as described previously (11). Labeled myelin basic protein (MAP) was separated by SDS-polyacrylamide gel electrophoresis and visualized by autoradiography (upper panel). The other half of the immunoprecipitates was subjected to Western blotting with anti-MAP kinase (lower panel).
[View Larger Version of this Image (44K GIF file)]


IRS-1:Phosphorylation and Association with PI3 Kinase

We next examined the signaling molecules IRS-1 and PI3 kinase, which were previously shown to be phosphorylated and activated by v-Ros (25). Our result shows that mutation of Tyr-419 specifically decreases the ability of v-Ros to cause tyrosine phosphorylation of IRS-1 (Fig. 6A). No such effect was observed for any of the other mutants, with the exception of the kinase inactive ones (data not shown). Consistent with the reduced phosphorylation of IRS-1, F419 protein also failed to promote association of PI3 kinase with IRS-1 as reflected in the in vitro PI3 kinase assay (Fig. 6B). This observation was confirmed by reciprocal immunoprecipitation and Western blotting using anti-p85 and anti-IRS-1 antibodies to detect their physical interaction. Association of IRS-1 with the 85 kDa subunit of PI3 kinase was observed in DI- and UR2-, but not in F419-infected cells.(data not shown). These results indicate that phosphorylation of IRS-1 and activation of PI3 kinase are not essential for promoting the growth of cells on monolayer culture.


Fig. 6. Tyrosine phosphorylation of IRS-1 and its association with PI3 kinase in F5- and DI-infected cells. A, cells were treated with 200 µM Na3VO4 for 4 h and then extracted with radioimmune precipitation buffer. 800 µg each of cell lysates were immunoprecipitated with anti-IRS-1 serum and subjected to Western blotting with anti-Tyr(P) antibody (RC20). Repeated experiments are shown. The bottom panel shows the IRS-1 protein from the equivalent immunoprecipitates of Exp. 1 and was analyzed by Western blotting with anti-IRS-1. B, IRS-1-associated PI3 kinase activity. Cells were extracted with Nonidet P-40 buffer. 500 µg each of cell lysates were immunoprecipitated with anti-IRS-1 serum, followed by PI3 kinase assay. The upper panel shows the autoradiography of one experiment. The histogram represents the combined quantitative analysis of the signals shown in the upper panel and two other independent experiments not shown here.
[View Larger Version of this Image (60K GIF file)]


Effect of v-Ros Mutations on Cytoskeleton-associated Proteins

Reorganization of cytoskeletal structure is intimately related to morphological transformation. The effect of cytoskeletal alteration on cell-to-cell and cell-to-matrix interactions could play an important role in the growth of cells in agar. We compared v-Ros and its mutant proteins for their ability to cause tyrosine phosphorylation and interaction of a series of cytoskeletal proteins involved in the formation of focal adhesion plaques and cell-cell interactions. No difference was observed among F419, DI, and UR2 PTKs in causing tyrosine phosphorylation of FAK, cortactin, paxillin, CAS (21), a Crk-associated protein, and annexin II (27), a cytoskeleton-associated Ca2+-dependent phospholipid binding protein (Fig. 7). Greatly increased tyrosine phosphorylation of annexin II, cortactin, and paxillin was observed in cell infected with wild-type v-Ros and the mutants. In contrast, the increase in tyrosine phosphorylation of FAK and CAS is only about 2-fold above the control CEF. We observed a tyrosine-phosphorylated 190-kDa protein associated with beta 1 integrin in UR2-, but much less in F419- and DI-infected cells. However, no significant tyrosine phosphorylation of integrin was detected (Fig. 8). In addition, tensin was more abundantly phosphorylated in UR2- than in the mutant-infected cells. Similarly, the p190 Rho/GAP was more highly phosphorylated in UR2- than in the mutant-infected cells, particularly in comparison with the F419 cells.


Fig. 7. Tyrosine phosphorylation of cytoskeleton-associated proteins. Cells were treated with 200 µM Na3VO4 for 4 h and extracted with radioimmune precipitation buffer. 500 µg each of cell lysate were immunoprecipitated with respective antibodies indicated, and duplicate immunoprecipitates were subjected to Western blotting with either anti-Tyr(P) antibody (RC20) (left panel) or the respective antibodies shown at the bottom of each right panel.
[View Larger Version of this Image (70K GIF file)]



Fig. 8. Tyrosine phosphorylation of integrin, tensin, and p190 Rho/GAP. Cells were treated and extracted as in Fig. 7. 500 µg to 1 mg each of total cell lysates were immunoprecipitated with the respective antibodies indicated at the bottom of each panel, and duplicate immunoprecipitates were analyzed by Western blotting with either anti-Tyr(P) antibody RC20 (upper two panels) or with the original antibody used for immunoprecipitation (bottom panels). Repeated experiments are shown. The bottom panels were derived from Exp. 1.
[View Larger Version of this Image (46K GIF file)]


For the proteins involved in cell-cell interaction, we observed significantly more abundant tyrosine phosphorylation of beta - and gamma -catenin, as well as more association between cadherin and beta -catenin, in UR2-, than in F419- and DI-infected cells(Fig. 9). Association of beta -catenin with cadherin was confirmed by Western blotting of the anti-cadherin immunoprecipitates with an anti-beta -catenin antibody (data not shown). Neither alpha -catenin nor cadherin was significantly tyrosine phosphorylated by any of our v-Ros proteins. These results indicate that F419 and DI proteins are either incapable or less effective in promoting tyrosine phosphorylation and interaction between various proteins involved in the formation of focal adhesion plaques and cell-cell interactions.


Fig. 9. Tyrosine phosphorylation and association of cadherin and catenins. Cells were treated and extracted as in Fig. 7. 500-600 µg each of total cell lysates were immunoprecipitated with the indicated antibody, and duplicate samples were analyzed similarly as described in Fig. 8. Repeated experiments are shown.
[View Larger Version of this Image (27K GIF file)]



DISCUSSION

This study identifies several sequences in v-Ros that play important roles in regulating PTK activity and cell transforming functions. The kinase positive and transformation-negative (K+T-) or attenuated (K+T±) mutants are useful in that they may allow identification of the signaling components essential for cell growth and transformation. We previously generated a mutant called TM1 by deleting 3 amino acids in the TM domain of v-Ros (Fig. 1) (25). This mutation has no effect on the kinase activity, but impairs both the mitogenic and transforming activities of v-Ros. The kinase-positive, mitogenicity positive but transformation-defective mutants (K+M+T±), represented by F419 and DI in this study, are thus particularly useful since they are selectively impaired in signaling pathways leading to distinct biological properties. Our results with F419 and DI indicate that activation of the Ras/MAP kinase pathway is not sufficient for cell transformation. Our data also suggest that the cytoskeletal protein-mediated signaling may be more closely related to morphological transformation and anchorage independent growth of cells. Numerous site-specific deletion mutants within the N-terminal region of v-Src have been reported to affect its ability to induce morphological transformation and promote colony formation in soft agar (28). However, it is not clear how those mutants affect the growth of cells on monolayer culture. Our F419 and DI mutants resemble a recently reported tyrosine 807 mutant in v-fms, which retains mitogenic but not morphological transforming activity (29).

Our data show that all the tyrosine residues in the cytoplasmic domain of gag-Ros, except for Tyr-419 and Tyr-564 are not individually required for Ros's biochemical and biological properties. Our finding of the effect of the triple tyrosine mutation cluster on v-Ros PTK activity is consistent with those of other RPTKs including IR (9) and IGFR (10, 11), which also contain such a tyrosine cluster. However, mutation of Tyr-418 of v-Ros, which corresponds to Tyr-1162 of IR, suggested to be the "gate-keeper" of its catalytic site (8), did not yield any detectable biochemical or biological effect on v-Ros. Instead, mutation of the third tyrosine Tyr-419 in the cluster resulted in the impairment of v-Ros-transforming ability and substrate specificity. This result is consistent with our previous observation on the mutation of the corresponding tyrosine residue Tyr-1136 of an oncogenic gag-IGFR fusion PTK except that the mutation in that case resulted in dramatic decrease of both mitogenic and transforming activity (11). Deletion of the 6-amino acid insertion near the catalytic loop of v-Ros resulted in the loss of in vitro kinase activity, but produces little effect on the in vivo tyrosine phosphorylation of the mutant DI protein. Moreover, the DI protein is able to induce tyrosine phosphorylation of the array of cellular substrates with a pattern indistinguishable from that of the wild-type v-Ros. The simplest explanation for this observation is that the deletion results in an enzyme whose conformation is relatively unstable and is easier to be inactivated during cellular protein extraction and in vitro processing. However, the possibility that the mutant DI protein is phosphorylated by other endogenous PTK(s) and becomes activated in vivo cannot be ruled out. If so, the active DI protein is apparently inactivated again during the protein extraction and processing since neither auto- nor trans-phosphorylation activity could be detected in vitro.

The IRS-1 and Shc recognition site on IR has been identified as the NPEY motif in the juxtamembrane region of IR, in which the N, P, and Y residues are important for the interaction (16). v-Ros is capable of inducing tyrosine phosphorylation of IRS-1 and Shc (25). However, there is no corresponding NPXY sequence in v-Ros. The Y419F mutation specifically decreases the tyrosine phosphorylation of IRS-1, but not of Shc. Therefore, the NDYY sequence of v-Ros likely defines an alternative recognition site for IRS-1. Shc may interact with v-Ros at another site. Alternatively, the presence of either of the twin tyrosines in NDYY may be sufficient for Shc recognition.

The Tyr-564 is the only residue that upon single mutation results in a pronounced reduction of intracellular autophosphorylation of v-Ros. Tryptic mapping of the in vitro autophosphorylated v-Ros proteins of UR2, F2 (Y418F/Y419F), and F564 revealed that several tryptic spots were missing in F564, but not in F2, protein in comparison with those of UR2 v-Ros protein (data not shown). These observations suggest that Tyr-564 is the major phosphorylation site of v-Ros in vitro and in vivo. Mutation of Tyr-564 also indicates that it is important for recognition of PLCgamma . The interaction site for PLCgamma maps to the carboxyl tyrosine residues of a number of RPTKs including EGF receptor (30), PDGF receptor (31), IGFR (11), and Met (32). Activation or overexpression of PLCgamma has been implicated in stimulating DNA synthesis and promoting cell transformation by EGF and PDGF receptors (33). Some other reports, however, concluded that PLCgamma was not important for PDGF-induced DNA synthesis (34). Our results shows that PLCgamma plays only a minor role in v-Ros-mediated transformation of CEF.

Activation of PI3 kinase has been implicated in diverse functions including mitogenesis (35, 36), GLUT4 translocation/glucose transport (35, 37), membrane ruffling (38), and activation of p70 S6 kinase that is involved in stimulating protein synthesis (35). Our result with F419 and DI suggests that PI3 kinase could play a significant role in v-Ros induced cell transformation, but its activation is insufficient for morphological transformation and anchorage-independent growth and is not important for growth in monolayer cultures.

Our data suggest that signaling involving cytoskeletal proteins and cell-cell interactions may play an important role in morphological transformation and anchorage independent growth. The Rho family of GTP-binding/GTPase proteins including, Rho, Rac, and CDC42 are key players in regulating the cytoskeletal structure and membrane properties and are also important in mediating Ras-induced cell transformation (39, 40). In this regard, it is intriguing that p190 Rho/GAP, a regulator of Rho, is underphosphorylated in the F419- and DI-infected, in comparison with the UR2-infected cells (Fig. 8). EGF-dependent actin cytoskeleton disassembly is modulated by expression of c-Src and correlates with increased tyrosine phosphorylation of p190 Rho/GAP (41). This phenomenon could be explained by increased activity of Rho/GAP resulting in diminished abundance of Rho/GTP needed to promote the formation of actin stress fibers.

Our observation of the increased tyrosine phosphorylation of tensin and a beta 1 integrin-associated 190-kDa protein, as well as cadherin-catenin complex involved in cell-cell interaction in UR2-, but not in F419- or DI-infected cells is also intriguing. It raises a possibility that those proteins are involved in mediating morphological transformation and anchorage-independent growth of UR2. Further work is required to elucidate the identity of the 190-kDa protein which we know is not p190Rho/GAP.

The cytoplasmic region of cadherin interacts with alpha -, beta - and gamma -catenins, which may serve as the bridge for interaction with actin, as well as signaling effectors (24). In v-Src-transformed cells, beta -catenin is tyrosine-phosphorylated, and although cadherins are expressed on the cell surface, they are functionally inactive (42). The homology between beta -catenin and a segment polarity gene in Drosophila called armadillo raises the possibility that beta -catenin has a similar role in developmental signaling (43). Thus, catenins may play a dual role in cell-cell interaction and in signaling. The increased tyrosine phosphorylation of catenins and their enhanced association with cadherin in v-Ros transformed cells may not only affect the function of cadherin, but also modulate the cytoplasmic pool of the catenin involved in signaling.


FOOTNOTES

*   This work was supported by National Institutes of Health Grant CA29339. The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Dagger    To whom correspondence should be addressed. Tel.: 212-241-3795; Fax: 212-534-1684; E-mail: wang{at}msvax.mssm.edu.
1    The abbreviations used are: RPTK, receptor protein-tyrosine kinase; PTK, protein-tyrosine kinase; PLCgamma , phospholipase Cgamma ; IRS-1, insulin receptor substrate 1; IGF, insulin-like growth factor; IGFR, insulin-like growth factor I receptor; IR, insulin receptor; CEF, chicken embryo fibroblast; PI3 kinase, phosphatidylinositol 3-kinase; v-Ros, the v-ros gene encoded gag-Ros fusion PTK protein; TM, transmembrane; PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FAK, focal adhesion protein; MAP, microtubule-associated protein.

REFERENCES

  1. Cantley, L. C., Auger, K. R., Carpenter, C., Duckworth, B., Granziani, A., Kapeller, R., and Soltoff, S. (1991) Cell 64, 281-302 [Medline] [Order article via Infotrieve]
  2. Neckameyer, W. S., and Wang, L.-H. (1985) J. Virol. 53, 879-884 [Medline] [Order article via Infotrieve]
  3. Birchmeier, C., O'Neill, K., Riggs, M., and Wigler, M. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 4799-4803 [Abstract]
  4. Chen, J., Heller, D., Poon, B., Kang, L., and Wang, L.-H. (1991) Oncogene 6, 257-264 [Medline] [Order article via Infotrieve]
  5. Matsushime, H., and Shibuya, M. (1990) J. Virol. 64, 2117-2125 [Medline] [Order article via Infotrieve]
  6. Jong, S.-M. J., and Wang, L.-H. (1987) Oncogene Res. 1, 7-21 [Medline] [Order article via Infotrieve]
  7. Zong, S. C., Poon, B., Chen, J., and Wang, L.-H. (1993) J. Virol. 67, 6453-6462 [Abstract]
  8. Hubbard, S. R., Wei, L., Ellis, L., and Hendrickson, W. A. (1994) Nature 372, 746-754 [CrossRef][Medline] [Order article via Infotrieve]
  9. Ellis, L., Clouser, E., Morgan, D. O., Edery, M., and Royh, R. A. (1986) Cell 45, 721-732 [Medline] [Order article via Infotrieve]
  10. Gronborg, M., Wulff, B. S., Rasmussen, J. S., Kjeldsen, T., and Gammeltoft, S. (1993) J. Biol. Chem. 268, 23435-23440 [Abstract/Free Full Text]
  11. Jiang, Y., Chan, J. L.-K., Zong, C. S., and Wang, L.-H. (1996) J. Biol. Chem. 271, 160-167 [Abstract/Free Full Text]
  12. Li, S., Ferber, A., Miura, M., and Baserga, R. (1994) J. Biol. Chem. 269, 32558-32564 [Abstract/Free Full Text]
  13. Pawson, T., and Gish, D. (1992) Cell 71, 359-362 [Medline] [Order article via Infotrieve]
  14. Hanks, S. K., Quinn, A. M., and Hunter, T. (1988) Science 241, 42-52 [Medline] [Order article via Infotrieve]
  15. Backer, J. M., Schroeder, G. G., Kahn, C. R., Myers, M. G., Jr., Wilden, P. A., Cahill, D. A., and White, M. F. (1992) J. Biol. Chem. 267, 1367-1374 [Abstract/Free Full Text]
  16. Gustafson, T. A., He, W., Craparo, A., Schau, C. D., and O'Neill, T. J. (1995) Mol. Cell. Biol. 15, 2500-2508 [Abstract]
  17. White, M. F., Livingston, J. N., Backer, J. M., Lauris, V., Dull, T. J., Ullrich, A., and Kahn, C. R. (1988) Cell 54, 641-649 [Medline] [Order article via Infotrieve]
  18. Blenis, J. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 5889-5892 [Abstract]
  19. Baltensperger, K., Kozma, L. M., Cherniack, A. D., Klarlund, J. K., Chawla, A., Banerjee, U., and Czech, M. P. (1993) Science 260, 1950-1952 [Medline] [Order article via Infotrieve]
  20. Myers, M. G., Backer, J. M., Jr., Sun, S. J., Shoelson, J., Hu, P., Schlessinger, J., Yoakim, M., Shaffhausen, B., and White, M. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 10350-10354 [Abstract]
  21. Sastry, S. K., and Horwitz, A. (1993) Cuur. Opin. Cell Biol. 5, 819-831 [Medline] [Order article via Infotrieve]
  22. Guan, J.-L., and Shalloway, D. (1992) Nature 358, 690-692 [CrossRef][Medline] [Order article via Infotrieve]
  23. Hildebrand, J. D., Schaller, M. D., and Parsons, J. T. (1993) J. Cell Biol. 123, 993-1005 [Abstract]
  24. Gumbiner, B. M., and McCrea, P. D. (1993) J. Cell Sci. Suppl. 17, 155-158 [Abstract]
  25. Zong, S. C., and Wang, L.-H. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10982-10986 [Abstract/Free Full Text]
  26. Liu, D., Rutter, W. J., and Wang, L.-H. (1993) J. Virol. 67, 9-18 [Abstract]
  27. Cooper, J., and Hunter, T. (1981) Mol. Cell. Biol. 1, 394-407 [Medline] [Order article via Infotrieve]
  28. Wang, H.-C. R., and Parsons, J. T. (1989) J. Virol. 63, 291-302 [Medline] [Order article via Infotrieve]
  29. Trouliaris, S., Smola, U., Chang, J. H., Parsons, S. J., Niemann, H., and Tamura, T. (1995) J. Virol. 69, 6010-6020 [Abstract]
  30. Rotin, D., Margolis, B., Mohammadi, M., Daly, R. J., Daum, G., Li, N., Fischer, E. H., Burgess, W. H., Ullrich, A., and Schlessinger, J. (1992) EMBO J. 11, 559-567 [Abstract]
  31. Kim, H, K., Kim, J. W., Zilberstein, A., Margolis, B., Kim, J. G., Schlessinger, J., and Rhee, S. G. (1991) Cell 65, 435-441 [Medline] [Order article via Infotrieve]
  32. Ponzetto, C., Bardelli, A., Zhen, Z., Maina, F., dalla Zonca, P., Giordano, S., Graziani, A., Panayotou, G., and Comoglio, P. M. (1994) Cell 77, 261-271 [Medline] [Order article via Infotrieve]
  33. Valius, M., and Kazlauskas, A. (1993) Cell 73, 321-334 [Medline] [Order article via Infotrieve]
  34. Hill, T. D., Dean, N. M., Mordan, L. J., Lau, A. F., Kanemitsu, Y. M., and Boynton, A. L. (1990) Science 248, 1660-1663 [Medline] [Order article via Infotrieve]
  35. Cheatham, B., Vlahos, C. J., Cheatham, L., Wang, L., Blenis, J., and Kahn, C. R. (1994) Mol. Cell. Biol. 14, 4902-4911 [Abstract]
  36. Kaplan, D. R., Whitman, M., Schaffhausen, B., Pallas, D. C., White, M., Cantley, L., and Roberts, T. M. (1987) Cell 50, 1021-1029 [Medline] [Order article via Infotrieve]
  37. Quon, M. J., Chen, H., Ing, B. L., Liu, M. L., Zarnowski, M. J., Yonezawa, K., Kasuga, M., Cushman, S. W., and Taylor, S. I. (1995) Mol. Cell. Biol. 15, 5403-5411 [Abstract]
  38. Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., and Downward, J. (1994) Nature 370, 527-532 [CrossRef][Medline] [Order article via Infotrieve]
  39. Nobesa, C. D., and Hall, A. (1995) Cell 81, 53-62 [Medline] [Order article via Infotrieve]
  40. Ridley, A. J., and Hall, A. (1992) Cell 70, 389-399 [Medline] [Order article via Infotrieve]
  41. Chang, J. H., Gill, S., Settleman, J., and Parsons, S. J. (1995) J. Cell Biol. 130, 355-368 [Abstract]
  42. Volberg, T., Geiger, B., Dror, R., and Zick, Y. (1991) Cell Regul. 2, 105-120 [Medline] [Order article via Infotrieve]
  43. McCrea, P. D., Turck, C. W., and Gumbiner, B. (1991) Science 254, 1359-1361 [Medline] [Order article via Infotrieve]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.